Miranda J. Payne

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.

Journal: BMJ open

Published: March 03, 2026

Sovereign AI supercomputers: a global landscape review of unprecedented biomedical research infrastructure.

Sovereign AI supercomputers: a global landscape review of unprecedented biomedical research infrastructure.

Journal: Frontiers in artificial intelligence

Published: January 26, 2026

Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK.

Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK.

Journal: The Lancet. Oncology

Published: December 25, 2025

Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery.

Immune Checkpoint Inhibitor Therapy Induced Hypophysitis; A Tertiary Care Centre Experience; Highlighting Detection, Treatment Outcomes and Long Term Endocrinopathies and Recovery.

Journal: Clinical endocrinology

Published: December 12, 2025

The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.

The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2025

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade.

Journal: Nature medicine

Published: December 23, 2024

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.

Journal: Journal for immunotherapy of cancer

Published: March 31, 2024

Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition.

Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition.

Journal: The Journal of laryngology and otology

Published: March 14, 2024

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 05, 2023

Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors.

Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors.

Journal: JAMA neurology

Published: July 11, 2022

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

Journal: Nature medicine

Published: April 06, 2022

Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma.

Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma.

Journal: Therapeutic advances in medical oncology

Published: March 01, 2022

Showing 1-12 of 40

Last Updated: 09/26/2026